Symbols

SLXN

Silexion·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About SLXN

Silexion Therapeutics Corp

A clinical stage biotechnology company specializing in oncology

Industry

Biological Technology

Established Date

Invalid Date

Listing Date

04/07/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.silexion.com

Security Type

Common stock

Office address

12 Abba Hillel Road, Ramat-Gan, Israel 5250606

Business

Introduction

Silexion Therapeutics Corp is a Cayman Islands exempted company. Silexion Therapeutics Ltd., a subsidiary of Biomotion Sciences. Silexion Therapeutics Ltd., is a clinical-stage, oncology-focused biotechnology company dedicated to the discovery and development of proprietary therapies for KRAS-driven cancers. Silexion's lead product candidate, SIL-204B, consists of locally administered small interfering RNAs or siRNAs in sustained-release formulations as the first-line treatment for patients with locally advanced pancreatic cancer in combination with standard of care chemotherapy. SIL-204B is the second-generation siRNA candidate following the Phase 1 and Phase 2 clinical trials of Silexion's first-generation siRNA candidate SIG12D-LODER (also known as Loder). The Phase 1 clinical trial met both primary and secondary endpoints, although the maximum tolerated dose was not established. In the Phase 2 clinical trial, although the primary endpoint for all patients was not met, the results showed a trend of difference between the treatment groups of patients with KRAS G12D/V mutations, with an overall survival advantage of 9.3 months in the Loder group. Regarding the secondary safety endpoint in the Phase 2 clinical trial, the endpoint was met. For secondary efficacy endpoints, no statistically significant differences were observed and there was insufficient data to evaluate. Due to the small size of the Phase 1 and Phase 2 trials, they did not provide statistical significance.

Company Financials

EPS

SLXN has released its 2025 Q2 earnings. EPS was reported at -4.32, versus the expected -3.15, missing expectations. The chart below visualizes how SLXN has performed over recent quarters, highlighting trends in earnings surprises.